This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

The Consumer Has a Point

Theodore Van Putten, MD; R. A. May, MD

Arch Gen Psychiatry. 1978;35(4):477-480.

Abstract
• Forty-two newly admitted patients with a schizophrenic illness were given a test dose of chlorpromazine, and their subjective response was graded on a euphoric-dysphoric continuum. Subjective response at 4, 24, and 48 hours after the test dose was significantly correlated with the subsequent outcome of a therapeutic course of treatment with chlorpromazine, as measured by the Brief Psychiatric Rating Scale, the Global Assessment Scale, and a write-in symptom scale. An early dysphoric response to chlorpromazine seemed to augur a poor prognosis for further treatment with the drug. These findings suggest that the subjective response to a test dose of chlorpromazine may be a useful predictor of short-term symptomatic outcome.

Author Affiliations
Philip

From the Department of Psychiatry, University of California at Los Angeles, and the Veterans Administration Hospital, Brentwood, Calif.

Footnotes
Accepted for publication May 10, 1977.

Reprint requests to Veterans Administration Hospital, Brentwood, Los Angeles, CA 90073 (Dr Van Putten).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Generic Correctional Programming for Mentally Ill Offenders: A Pilot Study
Ashford et al.
Criminal Justice and Behavior 2008;35:457-473.
ABSTRACT  

Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride
Linden et al.
J Psychopharmacol 2006;20:815-823.
ABSTRACT  

Prediction of functional outcome 18 months after a first psychotic episode: a proton magnetic resonance spectroscopy study.
Wood et al.
Arch Gen Psychiatry 2006;63:969-976.
ABSTRACT | FULL TEXT  

Attitudes Toward Antipsychotic Medication: The Impact of Clinical Variables and Relationships With Health Professionals
Day et al.
Arch Gen Psychiatry 2005;62:717-724.
ABSTRACT | FULL TEXT  

Adequacy of Treatment for Serious Mental Illness in the United States
Wang et al.
AJPH 2002;92:92-98.
ABSTRACT | FULL TEXT  

Non-Compliance With Treatment in Patients Suffering From Schizophrenia: a Study To Evaluate Possible Contributing Factors
Agarwal et al.
Int J Soc Psychiatry 1998;44:92-106.
ABSTRACT  

Psychopharmacology, Ethnicity and Culture
Lin et al.
Transcultural Psychiatry 1995;32:3-40.
 

Dose of Fluphenazine, Familial Expressed Emotion, and Outcome in Schizophrenia: Results of a Two-Year Controlled Study
Hogarty et al.
Arch Gen Psychiatry 1988;45:797-805.
ABSTRACT  

Toward a More Reliable Diagnosis of Akathisia
Van Putten and Marder
Arch Gen Psychiatry 1986;43:1015-1016.
ABSTRACT  

Subjective Response to Antipsychotic Drugs
Van Putten et al.
Arch Gen Psychiatry 1981;38:187-190.
ABSTRACT